BERKELEY, Calif., June 2 /PRNewswire/ -- A suite of gene family-based splice variant microarrays was launched today by Jivan Biologics, Inc., a privately held company. Manufactured by Agilent Technologies, Jivan's TransExpress(TM) Gene Family arrays enable researchers to detect and discover splicing events across entire gene families of therapeutic importance.
"With today's launch," said Subha Srinivisan, Ph.D., CEO and Founder of Jivan Biologics, "Jivan now offers catalogue arrays for alternate splicing for every stage of the drug development pipeline from target discovery, target validation and functional genomics to predictive toxicology, personalized medicine and the search for clinical markers in blood."
Every microarray in the TransExpress(TM) Gene Family suite is the first of its kind in the new splice variant array market.
With patent-pending technology for splice variant detection, the TransExpress(TM) Gene Family suite includes nine catalogue arrays each addressing a different therapeutically important gene family: G-protein coupled receptors (GPCRs), ion channels, kinases, phosphodiesterases (PDEs), cytochrome p450, phosphatases, proteases and proteinases, ATP-binding cassette (ABC) transporters and solute carriers.
Jivan began developing its first gene family array for alternate splicing in kinases in 2002 as part of a research collaboration with Sugen, Inc., a Pharmacia company, subsequently purchased by Pfizer. In 2003, Jivan launched its first catalogue splice array for phosphodiesterases, the gene family targeted by blockbuster drugs Cialis, Levitra and Viagra. In 2004, Jivan received an SBIR grant from the National Cancer Institute to develop a kinase splice array to find molecular signatures for cancer.
TransExpress(TM) arrays work with standard hybridization kits and scanners available from Agilent Technologies and other vendors.
This announcement follows Jivan's launch this week of the first whole genome splice variant array, TransExpress(TM) Whole Spliceome; the first splice variant array for clinical markers in blood, TransExpress(TM) Whole Blood; the first splice array for toxicology, TransExpress(TM) Toxicology; and the first catalogue splice array for cell signaling, TransExpress(TM) Cell Surface.
TransExpress(TM) microarrays for alternate splicing can be ordered online at http://www.jivanbio.com.
Jivan Biologics empowers scientists with new insight by providing a full catalogue of splice variant arrays for drug development and biological research. Available as a service since 2001 and as catalogue products since 2003, Jivan's flagship TransExpress(TM) arrays are the first commercial microarrays for alternate splicing.
Contact: Jonathan Bingham, 415-425-4115 Email: jbingham@jivanbio.comhttp://www.jivanbio.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Jivan Biologics, Inc.CONTACT: Jonathan Bingham of Jivan Biologics, +1-415-425-4115,jbingham@jivanbio.com
Web site: http://www.jivanbio.com//